McNeil KD - Search Results

1

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.

Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E. Strange G, et al. Among authors: mcneil kd. Respirology. 2008 Sep;13(5):674-82. doi: 10.1111/j.1440-1843.2008.01326.x. Respirology. 2008. PMID: 18713089

2

Review of bosentan in the management of pulmonary arterial hypertension.

Gabbay E, Fraser J, McNeil K. Gabbay E, et al. Vasc Health Risk Manag. 2007;3(6):887-900. Vasc Health Risk Manag. 2007. PMID: 18200808 Free PMC article. Review.

3

Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.

Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Keogh AM, et al. Among authors: mcneil kd. J Heart Lung Transplant. 2007 Feb;26(2):181-7. doi: 10.1016/j.healun.2006.11.009. J Heart Lung Transplant. 2007. PMID: 17258153 Clinical Trial.

4

The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.

Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, Wlodarczyk J, Dalton B. Keogh A, et al. Intern Med J. 2011 Mar;41(3):227-34. doi: 10.1111/j.1445-5994.2009.02139.x. Intern Med J. 2011. PMID: 20002851

5

Pulmonary arterial hypertension: a new era in management.

Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Keogh AM, et al. Among authors: mcneil kd. Med J Aust. 2003 Jun 2;178(11):564-7. doi: 10.5694/j.1326-5377.2003.tb05360.x. Med J Aust. 2003. PMID: 12765505 Review.

6

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.

Kotlyar E, Sy R, Keogh AM, Kermeen F, Macdonald PS, Hayward CS, McNeil KD, Celermajer DS. Kotlyar E, et al. Among authors: mcneil kd. Cardiol Young. 2006 Jun;16(3):268-74. doi: 10.1017/S1047951106000114. Cardiol Young. 2006. PMID: 16725066

7

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Wlodarczyk JH, Cleland LG, Keogh AM, McNeil KD, Perl K, Weintraub RG, Williams TJ. Wlodarczyk JH, et al. Among authors: mcneil kd. Pharmacoeconomics. 2006;24(9):903-15. doi: 10.2165/00019053-200624090-00007. Pharmacoeconomics. 2006. PMID: 16942124

8

Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension.

Dalton B, McNeil K, Keogh A, Williams T, Proudman S, Gabbay E, Kotlyar E, Weintraub R, Kermeen F, Celermajer D, Boland J. Dalton B, et al. Int J Clin Pract. 2012 Nov;66(11):1117-24. doi: 10.1111/j.1742-1241.2012.02997.x. Int J Clin Pract. 2012. PMID: 23067036

9

Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation.

Tuppin MP, Paratz JD, Chang AT, Seale HE, Walsh JR, Kermeeen FD, McNeil KD, Hopkins PM. Tuppin MP, et al. Among authors: mcneil kd. J Heart Lung Transplant. 2008 Jul;27(7):729-34. doi: 10.1016/j.healun.2008.03.017. Epub 2008 May 19. J Heart Lung Transplant. 2008. PMID: 18582801

10

Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.

Kermeen FD, Franks C, O'Brien K, Seale H, Hall K, McNeil K, Radford D. Kermeen FD, et al. Heart Lung Circ. 2010 Oct;19(10):595-600. doi: 10.1016/j.hlc.2010.07.005. Epub 2010 Aug 21. Heart Lung Circ. 2010. PMID: 20728407

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters